FDA approves Orca Bio’s T cell therapy for blood cancer patients ^65.3%

STAT - By Adam Feuerstein - 7/1/2026, 11:38 AM

Optimism Bias 50.9% - Attempt to Sell a Product or Service 50.9% - Ambiguity (Equivocation) 42.3%

The Food and Drug Administration on Tuesday approved a personalized T-cell therapy from Orca Bio, a private biotech company, that reduces the risk of a debilitating immune reaction in patients with blood cancers undergoing stem cell transplants. The Orca therapy, called Tregzi, represents an alternative approach to traditional... more